Live feed08:30:00·18dPRReleasevia QuantisnowOragenics Doses First Patient in Phase IIa Clinical Trial of ONP-002 for Mild Traumatic Brain InjuryByQuantisnow·Wall Street's wire, on your screen.OGEN· Oragenics Inc.Health Care
